TIDES: Oligonucleotides and Peptide Therapeutics’ Post

The latest EarthRate ESG Pharma and Biotech weekly (5.4.2024): - new Covid - cases at low levels in Europe - Q1 2024 Covid deaths in the US over 23.000 - Novo Nordisk and Nvidia to build AI supercomputer in Denmark - new healthcare listing in the US : Solventum in Nyse - most pharma stocks declined during the week's period Read the report here: www.pubplus.club #earthrate,#esginvesting #pharma #biotech

🚀Introducing HJB's Cutting-Edge Continuous Perfusion Platform! 🚀 We're excited to unveil HJB's highly productive continuous perfusion platform designed for the efficient production of all CHO-derived protein therapeutics, with exceptional productivity of up to 8 g/L-day (>15X fed-batch) achieved using in-house developed cell culture media. With such high productivities, a single 500L SUB can produce over 700 kg of drug substance per year, enabling smaller, cost-effective single-use facilities (<$120M) to produce over 4 metric tons of multi-product output. Additional key benefits include: ◙ Significant COGs reduction (>50%) ◙ Enhanced product quality control and consistency ◙ Just-in-time capacity to address demand uncertainties and accelerate speed to market ◙ Major sustainability gains in biomanufacturing lf you're interested in learning more, discussing your production needs, or implementing this platform in your company, let's connect! #Biotech #ContinuousPerfusion #Biomanufacturing #CostEfficiency #Sustainability #Innovation #HJB #Productivity #ICB Learn more: https://lnkd.in/gEbD62e8

Not only does Sweden have a thriving economy that largely depends on manufacturing and exports, but it also has a thriving life sciences sector. 🌟 In fact, did you know that, in 2020, the country’s life sciences sector recorded a net turnover of almost SEK 365 billion ($34 billion)? 💰 This marks an impressive increase of just over SEK 158 billion ($14.8 billion) since 2014. 📈 Read our latest article, as we take a look at eight Swedish companies spearheading the growth of the country’s biotech scene! 🔬🇸🇪 https://lnkd.in/dkMQYQUw #swedishbiotech #lifesciences #biotech #innovation #healthcare #economicgrowth #biotechindustry #manufacturing #biotechnews #pharma #biotechcompanies  #swedisheconomy Amferia | Anocca | Aprea Therapeutics | Asgard Therapeutics | BioInvent International AB | Diamyd Medical | Hamlet BioPharma | Modus Therapeutics Holding AB

Our incredible HJB team achieved the groundbreaking milestone of 8 g/L-day over a year ago. Learn more here: https://lnkd.in/eqAvC2Kh. This success is driven by a highly productive cell line expression system, our expertly developed in-house chemically defined perfusion cell culture media, and an efficient continuous perfusion platform. With such outstanding volumetric productivity, combined with our hybrid continuous DSP platform and advanced solution management technologies, the need for large, costly stainless-steel mega-facilities is eliminated. Instead, smaller, single-use multi-product facilities can be quickly built and made operational, offering the flexibility and agility to meet fluctuating demands (e.g., during pandemics) while ensuring consistent product quality and significantly reducing COGs. To learn more or explore how this technology can benefit your organization, contact us at https://lnkd.in/eyNNHV8Z.

🌟 Join Our Exclusive Manufacturing Roundtable Sessions (Track 3), Oligonucleotide Therapeutics Xchange, Boston. 🌟 Register for free: https://bit.ly/3wYHLnQ Are you passionate about the latest advancements in manufacturing and eager to stay ahead of the curve in the biotech industry? Don't miss out on our upcoming roundtable sessions, expertly tailored for you! 📅 Date: June 21, 2024 ⏰ Time: 08:00 - 17:40 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US ⭐ Here's the highlights: 📑 Downstream manufacturing challenges for synthetic oligonucleotides. 🗣️ Firoz Antia, Executive Director, Head of Oligonucleotide Development, Biogen 📑 Current challenges for drug substance CDMOs in the Oligonucleotide space. 🗣️ Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group 📑 Novel methodologies to manufacture Oligonucleotides. 🗣️ Mayur Patel, PhD, Director, Oligonucleotides Chemistry, Korro Bio, Inc. Our Partners 🔺 ChemGenes 🔺 PolyPeptide Group 🔺 Nitto Avecia 🔺 WuXi Biologics 🔺 Nostrum Biodiscovery 🔺 Vazyme Biotech * Agenda subject to change. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #Manufacturing #Biotech #Oligonucleotides #Networking #ProfessionalDevelopment #Pharma #Biotechnology #Chemistry #Science #Innovation #Roundtable #Roundtables #NetworkingEvent #IndustryLeaders #BusinessDevelopment #CareerGrowth #LearningOpportunity #NetworkingRoundtables #Research #Technology #Collaboration #Leadership #Expertise #Insights #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass

Happy New Year 2025! 🎉 Just before the holidays, WuXi Biologics was featured in the Irish Independent’s Future of Manufacturing Campaign, highlighting our Dundalk facility's role in Ireland’s biopharma ecosystem. In the article, our leaders—Brendan McGrath, Eimear McCarron, and Gene Russell —share their perspectives on how we’re advancing large-scale manufacturing, upholding world-class quality standards, and driving sustainability. From innovative single-use technology to our commitment to reducing environmental impact, the piece reflects how we’re shaping the future of biopharma with purpose and precision. Full article: https://lnkd.in/euNebkia Q&A: https://lnkd.in/enV54kKV

As we look ahead to 2025, we are excited to continue bringing you insightful, thought-provoking content on the Cytovance Biologics Ingenuity Blog. This year, the following posts sparked conversations and provided valuable insights into the world of biomanufacturing. Revisit them below and get ready for more expert analysis and updates to come in the new year! 🔗 Mammalian or Microbial? Considerations When Choosing an Expression System for Your Product -> https://hubs.la/Q030y5DQ0 🔗A Brief History of Microbial Biomanufacturing: Where We’ve Been and Where We Are Going -> https://hubs.la/Q030ylDh0 🔗Microbial Strain Development Strategy to Enhance Product Development -> https://hubs.la/Q030yh7x0 🔗5 Tips for Successfully Scaling from R&D to Manufacturing -> https://hubs.la/Q030yfm80 🔗 Beyond Conventional: How Cytovance’s CDMO Model is Empowering Emerging Biotechs -> https://hubs.la/Q030yp3B0 #biomanufacturing #biopharma #CDMO #drugdevelopment #TeamCytovance #blogpost

In an evolving biotech landscape, companies face critical choices about their manufacturing approaches, where quality, scalability, and cost considerations intersect. https://lnkd.in/eCwVUPW6 In this exclusive interview with Dr. Ulrich Rümenapp, Senior Biotech Program Lead at Bayer, he shares his insights on making informed, future-proof decisions for manufacturing in the biotech sector. Read the full interview here: https://lnkd.in/eCwVUPW6 #pharma #biotech #partnerships

Future of Biotech: Single-Use Bioreactors Market Projected at $10.0 Billion by 2028 𝐃𝐨𝐧'𝐭 𝐦𝐢𝐬𝐬 𝐨𝐮𝐭 𝐨𝐧 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭👉 https://lnkd.in/dxQBZ8pH The global single-use bioreactors market, valued at $4.2 billion in 2023, is expected to reach $10 billion by 2028, with a CAGR of 19.0%. Key market drivers include increasing adoption by startups and SMEs due to lower capital investments and operational simplicity compared to traditional systems. Despite growth, challenges like issues with extractables and leachables, and waste disposal concerns remain. The market segments into various product types and applications, with North America being the largest regional market. Hybrid manufacturing facilities present significant opportunities for sustainable production. 𝐓𝐨𝐩 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 Sartorius Danaher Corporation Thermo Fisher Scientific Merck KGaA, Darmstadt, Germany Getinge Eppendorf Entegris Avantor LOTTE BIOLOGICS Erbi Biosystems, a part of MilliporeSigma OmniBRx Biotechnologies Pvt Ltd Zencore Biologics #Biotech #Pharma #Bioreactors #SingleUse #Innovation #MarketTrends #Forecast2028

I am excited to share the news about the partnership between Cytovance Biologics and Celltheon which marks a significant advancement in biopharmaceuticals, particularly for complex biologics development and manufacturing. This collaboration combines Celltheon’s cutting-edge technologies with Cytovance’s integrated CDMO services, addressing key challenges in cell line development and cGMP manufacturing. Key Benefits of the strategic Partnership: Enhanced Development: OmniCHO™ Platform: Optimizes early-stage transient protein expression for high-yield production (1-4gm/L) and also accessing the developability and manufacturability of molecules. Goldilocks Transposase™: Ensures stable, high-efficiency gene integration for consistent and scalable protein production with early stable pool titers of 8-10gm/L and single clones at 10-12gm/L that are both very stable for over 60 generations. Comprehensive Manufacturing Solutions: Cytovance’s state-of-the-art facilities with 1000L and 2000L bioreactors enable efficient scale-up and commercial production. Strategic Customer Benefits: Reduced Timelines and Costs: Streamlined processes lower production costs and accelerate time-to-market. One-Stop Solution: Integrated cell line development, process optimization, and full-scale manufacturing enhance quality and consistency. Expanded Market Reach: Supports growing demand for biologics in US-based facilities, offering a complete platform solution from early-stage development to commercial production. Conclusion This partnership between Cytovance and Celltheon brings together leading technologies and manufacturing capabilities to deliver an integrated, scalable solution for mAbs and difficult-to-express proteins. It promises to drive significant advancements in biologics production, benefiting patients and healthcare providers by bringing innovative therapies to market more rapidly and reliably.